Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China

Acute myeloid leukaemia (AML) is the most common form of acute leukaemia in adults, with increasing incidence with age and a generally poor prognosis. Almost 20% of AML patients express mutant isocitrate dehydrogenase 2 (mIDH2), which leads to the accumulation of the carcinogenic metabolite 2-hydrox...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhiqiang, Zhang, Zhibo, Li, Yong, Sun, Li, Peng, Dezhen, Du, Danyu, Zhang, Xian, Han, Luwei, Zhao, Liwen, Lu, Ligong, Du, Hongzhi, Yuan, Shengtao, Zhan, Meixiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245910/
https://www.ncbi.nlm.nih.gov/pubmed/34221866
http://dx.doi.org/10.1016/j.apsb.2021.03.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245910/
https://www.ncbi.nlm.nih.gov/pubmed/34221866
http://dx.doi.org/10.1016/j.apsb.2021.03.005

Ejemplares similares